ArticleCell communication and signaling : CCS2026
ROR2 preserves alveolar bone homeostasis by orchestrating IRAK4-dependent suppression of CXCL8-driven osteolysis.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Alveolar bone resorption, driven by imbalanced osteogenesis and osteolysis, is a hallmark of periodontitis and orthodontic complications, yet molecular mechanisms coordinating stromal-immune crosstalk remain elusive. Here, we identify receptor tyrosine kinase-like orphan receptor 2 (ROR2) in alveolar bone-derived mesenchymal stem cells (ABMSCs) as a critical suppressor of inflammatory osteolysis. Using conditional knockout mice, we demonstrate that ROR2 deficiency in ABMSCs exacerbates alveolar bone loss by amplifying CXCL8 secretion, which enhances osteoclastogenesis while impairing osteogenic differentiation. Mechanistically, ROR2 sequesters interleukin-1 receptor-associated kinase 4 (IRAK4) via its Ig-like C2 domain, disrupting Myddosome assembly and downstream IRF7-driven CXCL8 transcription. Genetic ablation of IRAK4 in ROR2-deficient ABMSCs rescues pathological bone remodeling, restoring osteoblast-osteoclast equilibrium. Building on these findings, we engineer a thermosensitive chitosan/β-glycerophosphate hydrogel loaded with CXCL8-neutralizing antibodies, which effectively attenuates periodontitis-induced bone loss in vivo by suppressing osteoclast coverage and preserving osteogenic capacity. Our work unveils a ROR2/IRAK4/CXCL8 regulatory axis in ABMSCs that governs stromal-immune crosstalk during inflammatory osteolysis, offering a translatable strategy to recalibrate bone homeostasis in periodontal and orthodontic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.